Atrial selectivity of antiarrhythmic drugs

Journal of Physiology

Volumn 591, Issue 17, 2013, Pages 4087-4097

  Ravens, Ursula ^a   Poulet, Claire ^a   Wettwer, Erich ^a   Knaut, Michael ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b University Heart Center Dresden   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ACETYLCHOLINE REGULATED POTASSIUM CURRENT BLOCKER; AMINO ACID DERIVATIVE; ANTIARRHYTHMIC AGENT; APD PROLONGING DRUG; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; D,L SOTALOL; DOFETILIDE; DRONEDARONE; FLECAINIDE; IBUTILIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR3.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR3.4; MK 0448; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KV1.5; PROPAFENONE; RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.5; SOTALOL; TERIKALANT; TERTIAPIN Q; ULTRA RAPIDLY ACTIVATING OUTWARDLY RECTIFYING CURRENT BLOCKER; UNCLASSIFIED DRUG; VERNAKALANT; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL;

ACETYLCHOLINE REGULATED POTASSIUM CURRENT; ACTION POTENTIAL DURATION; ANTIARRHYTHMIC ACTIVITY; CARDIOSELECTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE EXCITABILITY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; ION CURRENT; NONHUMAN; PATHOPHYSIOLOGY; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; ULTRA RAPIDLY ACTIVATING OUTWARDLY RECTIFYING CURRENT; ACTION POTENTIAL; ANIMAL; ANTIBODY SPECIFICITY; ARRHYTHMIAS, CARDIAC; DRUG EFFECTS; HEART ATRIUM FUNCTION; HEART MUSCLE; METABOLISM;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FUNCTION; HUMANS; MYOCARDIUM; ORGAN SPECIFICITY; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 84883285860     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2013.256115     Document Type: Review

References (93)

1. Allessie M, Ausma J & Schotten U (2002). Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54, 230-246.
2. Altomare C, Barbuti A, Viscomi C, Baruscotti M & DiFrancesco D (2000). Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. Br J Pharmacol 130, 1315-1320.
3. Amos GJ, Wettwer E, Metzger F, Li Q, Himmel HM & Ravens U (1996). Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol 491, 31-50.
4. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM & Thomas G (2004). Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910.
5. Aonuma S, Kohama Y, Akai K, Komiyama Y, Nakajima S, Wakabayashi M & Makino T (1980). Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chem Pharm Bull (Tokyo) 28, 3332-3339.
6. Benito B, Brugada R, Perich RM, Lizotte E, Cinca J, Mont L, Berruezo A, Tolosana JM, Freixa X, Brugada P & Brugada J (2008). A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. Heart Rhythm 5, 1434-1440.
7. Bennett PB, Yazawa K, Makita N & George AL Jr (1995). Molecular mechanism for an inherited cardiac arrhythmia. Nature 376, 683-685.
8. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C & Kuhlkamp V (1999). Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 44, 121-131.
9. Kur promote atrial fibrillation Heart Rhythm 5, 1304-1309.
10. Burashnikov A & Antzelevitch C (2009). Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs 14, 233-249.
11. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L & Antzelevitch C (2007). Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116, 1449-1457.
12. Burashnikov A, Pourrier M, Gibson JK, Lynch JJ & Antzelevitch C (2012). Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and DL-sotalol. Circ Arrhythm Electrophysiol 5, 400-408.
13. Burstein B & Nattel S (2008). Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51, 802-809.
14. Camm AJ, Lip GY, De CR, Savelieva I, Atar D, Hohnloser SH, Hindricks G & Kirchhof P (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace 14, 1385-1413.
15. Cha TJ, Ehrlich JR, Chartier D, Qi XY, Xiao L & Nattel S (2006). Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 113, 1730-1737.
16. Chen LY, Ballew JD, Herron KJ, Rodeheffer RJ & Olson TM (2007). A common polymorphism in SCN5A is associated with lone atrial fibrillation. Clin Pharmacol Ther 81, 35-41.
17. K, ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol 154, 1619-1630.
18. Kur in patients with lone atrial fibrillation. Eur Heart J 34, 1517-1525.
19. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED & Keating MT (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795-803.
20. Deo M, Ruan Y, Pandit SV, Shah K, Berenfeld O, Blaufox A, Cerrone M, Noujaim SF, Denegri M, Jalife J & Priori SG (2013). KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. Proc Natl Acad Sci U S A 110, 4291-4296.
21. Dhein S, Hagen A, Jozwiak J, Dietze A, Garbade J, Barten M, Kostelka M & Mohr FW (2010). Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides. Naunyn Schmiedebergs Arch Pharmacol 381, 221-234.
22. Dobrev D, Carlsson L & Nattel S (2012). Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 11, 275-291.
23. K, ACh is constitutively active in patients with chronic atrial fibrillation. Circulation 112, 3697-3706.
24. K, ACh and muscarinic receptor-mediated shortening of action potentials. Circulation 104, 2551-2557.
25. Dobrev D & Ravens U (2003). Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol 98, 137-148.
26. 2+ signals confer fibrogenesis in human atrial fibrillation. Circ Res 106, 992-1003.
27. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324, 781-788.
28. Ehrlich JR, Hoche C, Coutu P, Metz-Weidmann C, Dittrich W, Hohnloser SH, Nattel S & Gögelein H (2006). Properties of a time-dependent potassium current in pig atrium: evidence for a role of Kv1.5 in repolarization. J Pharmacol Exp Ther 319, 898-906.
29. Ehrlich JR, Nattel S & Hohnloser SH (2007). Novel anti-arrhythmic drugs for atrial fibrillation management. Curr Vasc Pharmacol 5, 185-195.
30. + current in canine atrial myocytes. Circ Res 93, 744-751.
31. + channel current. Circ Res 73, 210-216.
32. Firouzi M, Ramanna H, Kok B, Jongsma HJ, Koeleman BP, Doevendans PA, Groenewegen WA & Hauer RN (2004). Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ Res 95, e29-e33.
33. Kur inhibitor. J Cardiovasc Pharmacol 61, 408-419.
34. Kur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol 52, 105-120.
35. Gintant GA (2000). Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization. Am J Physiol Heart Circ Physiol 278, H806-H817.
36. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P & Clementy J (1998). Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339, 659-666.
37. Harada M, Luo X, Qi XY, Tadevosyan A, Maguy A, Ordog B, Ledoux J, Kato T, Naud P, Voigt N, Shi Y, Kamiya K, Murohara T, Kodama I, Tardif JC, Schotten U, Van Wagoner DR, Dobrev D & Nattel S (2012). Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation 126, 2051-2064.
38. KACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res 54, 136-141.
39. Kr-blocker dofetilide. J Cardiovasc Pharmacol 51, 162-169.
40. Hondeghem LM & Katzung BG (1984). Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol 24, 387-423.
41. Hondeghem LM & Snyders DJ (1990). Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81, 686-690.
42. + channels. Biochemistry 38, 14286-14293.
43. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S & Breithardt G (2009). Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 30, 2969-77c.
44. Kjolbye AL, Knudsen CB, Jepsen T, Larsen BD & Petersen JS (2003). Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in vivo and in vitro studies. J Pharmacol Exp Ther 306, 1191-1199.
45. KACh in atrial fibrillation using a mouse knockout model. J Am Coll Cardiol 37, 2136-2143.
46. +-channel proteins. Nature 374, 135-141.
47. + current in human ventricular myocytes. Circ Res 78, 689-696.
48. Lubitz SA, Ozcan C, Magnani JW, Kaab S, Benjamin EJ & Ellinor PT (2010). Genetics of atrial fibrillation: implications for future research directions and personalized medicine. Circ Arrhythm Electrophysiol 3, 291-299.
49. + channel blocker on experimental atrial fibrillation. Circ Arrhythm Electrophysiol 4, 94-102.
50. Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, Dupuis J, Ellinor PT & Benjamin EJ (2011). Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation 124, 1982-1993.
51. Maltsev VA, Silverman N, Sabbah HN & Undrovinas AI (2007). Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail 9, 219-227.
52. Maltsev VA & Undrovinas A (2008). Late sodium current in failing heart: friend or foe Prog Biophys Mol Biol 96, 421-451.
53. Matsuda T, Ito M, Ishimaru S, Tsuruoka N, Saito T, Iida-Tanaka N, Hashimoto N, Yamashita T, Tsuruzoe N, Tanaka H & Shigenobu K (2006). Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 channel. J Pharmacol Sci 101, 303-310.
54. Mitcheson JS, Chen J, Lin M, Culberson C & Sanguinetti MC (2000). A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97, 12329-12333.
55. Mori K, Hara Y, Saito T, Masuda Y & Nakaya H (1995). Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms. Circulation 91, 2834-2843.
56. Narayan SM, Krummen DE, Enyeart MW & Rappel WJ (2012). Computational mapping identifies localized mechanisms for ablation of atrial fibrillation. PLoS One 7, e46034.
57. Nattel S & Dobrev D (2012). The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 33, 1870-1877.
58. Nattel S, Yue L & Wang Z (1999). Cardiac ultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity. Cell Physiol Biochem 9, 217-226.
59. + current and experimental atrial fibrillation in guinea-pig hearts. J Pharmacol Sci 105, 229-239.
60. Nishida K, Michael G, Dobrev D & Nattel S (2010). Animal models for atrial fibrillation: clinical insights and scientific opportunities. Europace 12, 160-172.
61. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A & Terzic A (2006). Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 15, 2185-2191.
62. Pandit SV & Jalife J (2013). Rotors and the dynamics of cardiac fibrillation. Circ Res 112, 849-862.
63. Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE & Bloomfield D (2012). MK-0448, a specific Kv1.5 inhibitor: Safety, pharmacokinetics and pharmacodynamic electrophysiology in experimental animal models and in humans. Circ Arrhythm Electrophysiol 5, 1193-1201.
64. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, Kuhn-Regnier F, De Vivie ER & Dhein S (2001). Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 38, 883-891.
65. Ravens U (1976). Electromechanical studies of an Anemonia sulcata toxin in mammalian cardiac muscle. Naunyn Schmiedebergs Arch Pharmacol 296, 73-78.
66. Ravens U (2010). Antiarrhythmic therapy in atrial fibrillation. Pharmacol Ther 128, 129-145.
67. Ravens U & Wettwer E (2011). Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc Res 89, 776-785.
68. Sakakibara Y, Furukawa T, Singer DH, Jia H, Backer CL, Arentzen CE & Wasserstrom JA (1993). Sodium current in isolated human ventricular myocytes. Am J Physiol Heart Circ Physiol 265, H1301-H1309.
69. Sakakibara Y, Wasserstrom JA, Furukawa T, Jia H, Arentzen CE, Hartz RS & Singer DH (1992). Characterization of the sodium current in single human atrial myocytes. Circ Res 71, 535-546.
70. Savelieva I & Camm J (2008). Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 10, 647-665.
71. 2+-exchange. Cardiovasc Res 73, 37-47.
72. Schotten U, Verheule S, Kirchhof P & Goette A (2011). Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91, 265-325.
73. Snyders DJ, Tamkun MM & Bennett PB (1993). A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 101, 513-543.
74. + currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 55, 2330-2342.
75. Spach MS, Barr RC & Jewett PH (1972). Spread of excitation from the atrium into thoracic veins in human beings and dogs. Am J Cardiol 30, 844-854.
76. Starmer CF, Grant AO & Strauss HC (1984). Mechanisms of use-dependent block of sodium channels in excitable membranes by local anaesthetics. Biophys J 46, 15-27.
77. Sun Y, Yang YQ, Gong XQ, Wang XH, Li RG, Tan HW, Liu X, Fang WY & Bai D (2013). Novel germline GJA5/Connexin40 mutations associated with lone atrial fibrillation impair gap junctional intercellular communication. Hum Mutat 34, 603-609.
78. Kur/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs 18, 399-416.
79. + channel cDNAs from human ventricle. FASEB J 5, 331-337.
80. Toussaint D, Christ T, Wettwer E & Ravens U (2011). Late sodium current as a promising antiarrhythmic drug target for treatment of atrial fibrillation Naunyn Schmiedebergs Arch Pharmacol 383, 61.
81. Undrovinas AI, Maltsev VA & Sabbah HN (1999). Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci 55, 494-505.
82. Vaughan Williams EM (1975). Classification of antidysrhythmic drugs. Pharmacol Ther B 1, 115-138.
83. K, ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 381, 251-259.
84. Wakili R, Voigt N, Kaab S, Dobrev D & Nattel S (2011). Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 121, 2955-2968.
85. + current similar to Kv1.5 cloned channel currents. Circ Res 73, 1061-1076.
86. Wettwer E, Christ T, Endig S, Rozmaritsa N, Matschke K, Lynch JJ, Pourrier M, Gibson JK, Fedida D, Knaut M & Ravens U (2013). The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc Res 98, 145-154.
87. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110, 2299-2306.
88. Wijffels MC, Kirchhof CJ, Dorland R & Allessie MA (1995). Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968.
89. Xia M, Jin Q, Bendahhou S, He Y, Larroque MM, Chen Y, Zhou Q, Yang Y, Liu Y, Liu B, Zhu Q, Zhou Y, Lin J, Liang B, Li L, Dong X, Pan Z, Wang R, Wan H, Qiu W, Xu W, Eurlings P, Barhanin J & Chen Y (2005). A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun 332, 1012-1019.
90. Yamada M, Inanobe A & Kurachi Y (1998). G protein regulation of potassium ion channels. Pharmacol Rev 50, 723-760.
91. Yue L, Xie J & Nattel S (2011). Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 89, 744-753.
92. Yue Z, Zhang Y, Xie J, Jiang J & Yue L (2013). Transient receptor potential (TRP) channels and cardiac fibrosis. Curr Top Med Chem 13, 270-282.
93. Zaza A, Belardinelli L & Shryock JC (2008). Pathophysiology and pharmacology of the cardiac "late sodium current". Pharmacol Ther 119, 326-339.